Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
about
The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosisThe significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosisAnomalous venous blood flow and iron deposition in multiple sclerosis.Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients.Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a.Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activityTranslational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureTh17 cells in human disease.Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.Cleavage of myelin associated glycoprotein by matrix metalloproteinases.Astrocytes--friends or foes in multiple sclerosis?Microglia/macrophage-derived inflammatory mediators galectin-3 and quinolinic acid are elevated in cerebrospinal fluid from newborn infants after birth asphyxiaDisruption of the blood-brain barrier after generalized tonic-clonic seizures correlates with cerebrospinal fluid MMP-9 levels.Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis PatientsEfficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis.Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta.Cerebrospinal fluid in multiple sclerosis.The Characterization of GSDMB Splicing and Backsplicing Profiles Identifies Novel Isoforms and a Circular RNA That Are Dysregulated in Multiple Sclerosis.Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding.The effect of 1, 25(OH)2 D3 (calcitriol) alone and in combination with all-trans retinoic acid on ROR-γt, IL-17, TGF-β, and FOXP3 gene expression in experimental autoimmune encephalomyelitis.The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up.Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of children with Japanese encephalitis virus infection.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.The role of MMP genes in recurrent depressive disorders and cognitive functions.TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis.Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier.Detection of Matrix Metalloproteinases by Zymography.Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics.Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes
P2860
Q24675908-8B315B6A-1368-44F0-A698-189365E11BDCQ27009126-0582C0E5-4A0C-4D69-81D1-F6B2671016DEQ33499203-94DED8D1-89D5-43A8-94FF-D20B37B63EBFQ33700802-27A2AC9A-054A-4C45-B6B7-F16DFCAEE7A7Q34109028-942FB731-5D29-46F1-8216-CF5F2F7118B9Q34980198-6FBC2174-C8F3-48CC-8C40-4FE2734898C2Q34999439-0B96D564-60EA-4CC6-AEE8-0CDD7A83971AQ35012792-053164BF-251D-47C5-BB23-F4D63BB92CA1Q35078327-1AF065AD-7CBB-4AE4-98CE-BE59407075AEQ35820734-C741B39B-3844-4581-8024-D293918B9C33Q35987823-877CDBAB-8159-46F3-8B43-6B0084BC9899Q36160459-1A578417-A7DB-4DD8-88F8-F35921711F17Q36513220-4DC84D80-0624-4D67-B8F3-2451227ACC77Q36878427-D96940F5-9F81-48A2-8910-00E91EF85F1DQ36937939-FA78DDC7-8B4A-42A0-9806-D52D1164158FQ36996481-162A82AB-35C6-40F5-9D75-A8752F1B23D9Q37009992-031CFB58-4951-4F8F-9C4F-3B2D4D2E94A3Q37171985-C54EA14F-86C5-479B-ADA3-E2916174606AQ37311605-E67196A7-E01F-4636-B6E2-75981DB91F60Q37402058-D134D4D2-C6C4-4449-9AB2-95DB235844D8Q37698240-A99DFADD-FAD4-4E5E-96CD-E406DF5A6DB5Q37729175-44317910-0B1A-40BA-B3C3-099409CD2793Q37859376-ABAFB4A4-26D6-45E0-B316-6CE6DE676555Q38802998-AE8ACE6E-FA5E-465E-B498-A01190076E13Q39143880-9A173B0F-079A-4577-A43F-1F6D92B8ACA8Q40416300-9A67B866-9140-482B-9206-F4D68360EBC1Q41060238-BDC0C857-CC78-4B52-8864-D3DA9BCB7274Q41236543-2B9A0113-2400-499E-88FF-47CB39F46C36Q42285234-AC087D70-8939-4F68-A3F8-65D1B6DC7941Q47638443-B03C53EE-0A9B-43AF-9713-9FA2B6AAF37EQ47707801-23FD127C-5FBE-40D4-91EA-DD340C7AB756Q48064458-701FCE73-F06D-4791-954D-1746477EE144Q48338849-011E7ED1-E955-4AC4-83C7-35BF1526A2EEQ48434563-9CBCAAD7-D882-4DA8-B499-149CB5F54180Q50318079-0ED038E0-0ED7-413D-A5EF-AD34704011AEQ50781209-A8713592-AB11-481D-9444-DC7F15A9EAA2Q55379242-81126608-3C93-4D31-A0A4-A0C466E3462FQ58774884-8AAC397E-6CAE-4529-9047-2187B01D8181
P2860
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Cerebrospinal fluid and serum ...... ients with multiple sclerosis.
@en
Cerebrospinal fluid and serum ...... ive matrix metalloproteinase-9
@nl
type
label
Cerebrospinal fluid and serum ...... ients with multiple sclerosis.
@en
Cerebrospinal fluid and serum ...... ive matrix metalloproteinase-9
@nl
prefLabel
Cerebrospinal fluid and serum ...... ients with multiple sclerosis.
@en
Cerebrospinal fluid and serum ...... ive matrix metalloproteinase-9
@nl
P2093
P2860
P50
P1476
Cerebrospinal fluid and serum ...... tients with multiple sclerosis
@en
P2093
P2860
P304
P356
10.1191/135248506MS1274OA
P577
2006-06-01T00:00:00Z